Literature DB >> 16539837

Aquaporins as potential drug targets.

Fang Wang1, Xue-Chao Feng, Yong-Ming Li, Hong Yang, Tong-Hui Ma.   

Abstract

The aquaporins (AQP) are a family of integral membrane proteins that selectively transport water and, in some cases, small neutral solutes such as glycerol and urea. Thirteen mammalian AQP have been molecularly identified and localized to various epithelial, endothelial and other tissues. Phenotype studies of transgenic mouse models of AQP knockout, mutation, and in some cases humans with AQP mutations have demonstrated essential roles for AQP in mammalian physiology and pathophysiology, including urinary concentrating function, exocrine glandular fluid secretion, brain edema formation, regulation of intracranial and intraocular pressure, skin hydration, fat metabolism, tumor angiogenesis and cell migration. These studies suggest that AQP may be potential drug targets for not only new diuretic reagents for various forms of pathological water retention, but also targets for novel therapy of brain edema, inflammatory disease, glaucoma, obesity, and cancer. However, potent AQP modulators for in vivo application remain to be discovered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16539837     DOI: 10.1111/j.1745-7254.2006.00318.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  13 in total

1.  P2Y(2) receptors and water transport in the kidney.

Authors:  Bellamkonda K Kishore; Raoul D Nelson; R Lance Miller; Noel G Carlson; Donald E Kohan
Journal:  Purinergic Signal       Date:  2009-03-25       Impact factor: 3.765

2.  AQP1 mediates water transport in the carotid body.

Authors:  Ana M Muñoz-Cabello; Javier Villadiego; Juan J Toledo-Aral; José López-Barneo; Miriam Echevarría
Journal:  Pflugers Arch       Date:  2010-01-05       Impact factor: 3.657

Review 3.  Revisiting the metabolic syndrome: the emerging role of aquaglyceroporins.

Authors:  Inês Vieira da Silva; Joana S Rodrigues; Irene Rebelo; Joana P G Miranda; Graça Soveral
Journal:  Cell Mol Life Sci       Date:  2018-02-20       Impact factor: 9.261

Review 4.  Aquaporin-Targeted Therapeutics: State-of-the-Field.

Authors:  Lukmanee Tradtrantip; Bjung-Ju Jin; Xiaoming Yao; Marc O Anderson; Alan S Verkman
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Experimental Evaluation of Proposed Small-Molecule Inhibitors of Water Channel Aquaporin-1.

Authors:  Cristina Esteva-Font; Byung-Ju Jin; Sujin Lee; Puay-Wah Phuan; Marc O Anderson; A S Verkman
Journal:  Mol Pharmacol       Date:  2016-03-18       Impact factor: 4.436

6.  Membrane domain specificity in the spatial distribution of aquaporins 5, 7, 9, and 11 in efferent ducts and epididymis of rats.

Authors:  Louis Hermo; Morgan Schellenberg; Lauren Ye Liu; Bama Dayanandan; Tong Zhang; Craig A Mandato; Charles E Smith
Journal:  J Histochem Cytochem       Date:  2008-09-15       Impact factor: 2.479

7.  Development of a Novel Ligand, [C]TGN-020, for Aquaporin 4 Positron Emission Tomography Imaging.

Authors:  Yukihiro Nakamura; Yuji Suzuki; Mika Tsujita; Vincent J Huber; Kenichi Yamada; Tsutomu Nakada
Journal:  ACS Chem Neurosci       Date:  2011-06-27       Impact factor: 4.418

8.  Down-regulated aquaporin 5 inhibits proliferation and migration of human epithelial ovarian cancer 3AO cells.

Authors:  ChunXiao Yan; Yunshan Zhu; Xiao Zhang; Xuejun Chen; Wei Zheng; Jianhua Yang
Journal:  J Ovarian Res       Date:  2014-08-15       Impact factor: 4.234

9.  Endothelial Aquaporins and Hypomethylation: Potential Implications for Atherosclerosis and Cardiovascular Disease.

Authors:  Inês Vieira da Silva; Madalena Barroso; Teresa Moura; Rita Castro; Graça Soveral
Journal:  Int J Mol Sci       Date:  2018-01-03       Impact factor: 5.923

10.  Exploring the role of Aquaporins (AQPs) in LPS induced systemic inflammation and the ameliorative effect of Garcinia in male Wistar rat.

Authors:  Anuradha Kalita; Manas Das; Momita Rani Baro; Bhabajyoti Das
Journal:  Inflammopharmacology       Date:  2021-06-09       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.